BPC-157 and Gut Healing: The Original Discovery Nobody

BPC-157 was discovered in human gastric juice. Not in tendons, not in ligaments — in the stomach. The original research, conducted by a Croatian team led by Predrag Sikiric at the University of Zagreb, focused on gastroprotection. The tendon-healing properties that made BPC-157 famous in fitness circles were discovered later, almost by accident.

This matters because the gut-healing evidence base is actually stronger than the musculoskeletal one. And for fitness professionals whose clients often struggle with GI issues — from IBS to leaky gut to NSAID-induced stomach damage — this is the application most likely to be relevant.

The Original Research Program

Sikiric's lab began investigating BPC-157 in the 1990s. Their initial focus was on gastric and duodenal ulcers. Across dozens of studies, they demonstrated that BPC-157:

• Healed gastric lesions in rat models
• Protected against NSAID-induced gastric damage (indomethacin, aspirin)
• Healed duodenal ulcers
• Reversed fatal peritonitis in rat models
• Protected against pancreatic, hepatic, and intestinal damage

The mechanism was consistent with what was later found in tendon healing: VEGFR2-Akt-eNOS activation, angiogenesis, and enhanced tissue repair.

The Gut-Joint Connection

Here is where it gets interesting for the fitness world. The gut-joint axis is increasingly recognized in sports medicine. Chronic gut inflammation drives systemic inflammation, which worsens joint pain and slows recovery. Athletes who take NSAIDs for joint pain often create a vicious cycle: NSAIDs damage the gut lining, gut inflammation increases systemic inflammation, joint pain worsens, more NSAIDs are needed.

BPC-157's dual action — healing both the gut and the joints — addresses both sides of this cycle. The 2025 IJMS review (PMC12944561) documented BPC-157's efficacy across gastrointestinal, musculoskeletal, and neurological systems, suggesting a unified mechanism of tissue repair.

What the Evidence Supports

• NSAID-induced gastric damage: Multiple rat studies show BPC-157 prevents and heals NSAID-induced lesions. This is the strongest preclinical application.
• Inflammatory bowel disease: Rat models of colitis showed significant improvement with BPC-157 treatment.
• Leaky gut (intestinal permeability): BPC-157 was shown to restore intestinal epithelial integrity in animal models.
• Gut-brain axis: Emerging evidence (animal models) suggests BPC-157 modulates serotonin and dopamine systems, potentially explaining anecdotal reports of improved mood.

The Human Data Gap

As with musculoskeletal applications, human clinical data is nearly nonexistent. The Sikiric group published one pilot study involving 12 women with bladder pain syndrome (related to pelvic floor inflammation, not directly gut). There are no published RCTs for any gastrointestinal indication.

Practical Implications

For trainers, the gut-healing angle is potentially more relevant than the tendon-healing angle because:

1. More clients struggle with GI issues than with tendon injuries
2. The NSAID-damage cycle is common in athletic populations
3. Gut health directly affects nutrient absorption, energy levels, and recovery

But the same caveat applies: promising animal data does not equal proven human therapy. Clients with GI issues should work with a gastroenterologist, not self-medicate with unregulated peptides.

References

1. Sikiric, P., et al. (2025). BPC 157 — A Review. Int J Mol Sci, 27(6), 2876. PMC12944561.
2. Sikiric, P., et al. (2023). BPC-157 and the gastroprotective effects. Narrative review.
3. Vasireddi, N., et al. (2025). HSS Journal, 21(4). DOI: 10.1177/15563316251355551
4. Examine.com BPC-157 review (2025).

This article is for informational purposes only and does not constitute medical advice.